Objective. To examine drug treatment in nursing home patients at the end of life, and identify predictors of palliative drug therapy. Design. A historical cohort study. Setting. Three urban nursing homes in Norway. Subjects. All patients admitted from January 2008 and deceased before February 2013. Main outcome measures. Drug prescriptions, diagnoses, and demographic data were collected from electronic patient records. Palliative end-of-life drug treatment was defi ned on the basis of indication, drug, and formulation. Results. 524 patients were included, median (range) age at death 86 (19 -104) years, 59% women. On the day of death, 99.4% of the study population had active prescriptions; 74.2% had palliative drugs either alone (26.9%) or concomitantly with curative/preventive drugs (47.3%). Palliative drugs were associated with nursing home, length of stay Ͼ 16 months (AOR 2.10, 95% CI 1.12 -3.94), age (1.03, 1.005 -1.05), and a diagnosis of cancer (2.12, 1.19 -3.76). Most initiations of palliative drugs and withdrawals of curative/preventive drugs took place on the day of death. Conclusion. Palliative drug therapy and drug therapy changes are common for nursing home patients on the last day of life. Improvements in end-of-life care in nursing homes imply addressing prognostication and earlier response to palliative needs.
Introduction
In Norway, 47.5% of deaths occur in nursing homes (NHs), 32.5% in hospitals, and 14.5% at home [1] . About 95% of patients in long-term care will die in the institution [2] . NH patients are prescribed a wider range of medications than any other subpopulation [3, 4] . For the dying patient, standing drug treatments must be reconsidered and often discontinued. The last days of life are often characterized by symptoms such as pain, respiratory distress, and anxiety, as well as inability to take oral medications [5] . These symptoms may be palliated by parenterally administered drugs [6] .
Whereas palliative literature has a main focus on specialized care for patients with cancer in hospice and hospital, including a range of drug therapy options for the dying [6 -8] , international consensus on palliative end-of-life (EOL) drug treatment for
Material and methods

Study population
NHs in Norway accommodate around 41 000 beds, corresponding to 18% of the general population 80 years and older. All NHs provide EOL care, but only 42 institutions have specialized palliative care units. Most NH physicians in Norway are part-time engaged general practitioners [1] . The study population comprised all patients in three urban NHs in Norway admitted from January 2008 and deceased before February 2013. The institutions were selected on the basis of using an electronic patient record system optimized for data extraction [10] .
Data collection
We collected routinely registered data from the patients ' fi nal NH stay: demographic data (age, gender, date of NH admission and death, long-or short-term stay); diagnoses (ICD-10) [11] ; medications (generic name, Anatomical Therapeutic Chemical (ATC) code [12] , drug formulation, regular or as-needed schedule, indication, dates of initiation, alteration, or discontinuation). An external IT consultant extracted the data, and replaced ID-numbers with a running number, the key to which remained undisclosed to the research group.
Drug therapy
We defi ned palliative EOL drug therapy in NHs on the basis of indication, drug, and formulation; (1) any drug prescription with an explicit EOL care indication key word was included: palliative, terminal, death, death rattle, Liverpool Care Pathway, or EOL; (2) we also included prescriptions of specifically recommended injectable palliative EOL drugs for use in NHs [2, 5] , regardless of missing EOL key words in the indication text (Table I) . " Curative/ preventive drug therapy " , in contrast, was defi ned as medication for regular use without an explicit EOL care indication.
Statistical analysis
User rates were established for drugs according to the above categories. We explored predictors of palliative EOL drug therapy by a chi-squared test, and subsequently by binary logistic regression analysis; dependent variable: palliative EOL drug therapy; independent variables: age, gender, length of stay, nursing home, diagnosis of cancer. All variables but age were analysed as categorical. Signifi cance was determined at a level of 5%. IBM SPSS Statistics 20 (SPSS Inc., Chicago, Ill., USA) was used for statistical analyses.
Results
Patient characteristics
The study population comprised 524 deceased patients. Median (range) age at death was 86 (19 -104) years, 59.4% were women, 68.1% in longterm care. The most common registered diagnoses were dementia (36.8% of the patients), congestive heart failure (29.6%), and cancer (23.7%) ( Table II (p Ͻ 0.01), as the EPR data were collected from was used only in the long-term ward.
Patients with cancer more frequently died within two weeks of admission than patients without cancer (41.1% vs. 20.5%, p Ͻ 0.01). Patients with dementia more frequently died after stays of longer than 16 months compared with patients without this diagnosis (40.4% vs. 16.0%, p Ͻ 0.01).
Drug use on the day of death
On the day of death, 99.4% of the study population were on drug therapy. The most common regular and as-needed drugs are shown in Table III .
Of the 4736 standing prescriptions (regular and as-needed drugs) on the day of death, palliative EOL drugs comprised 1306 (27.6%) and curative/ preventive drugs 2419 (51.1%), while 1011 (21.3%) prescriptions were not classifi ed in either category. Indication was documented for 99.6% of all drugs on the day of death.
Altogether 50.2% of patients were prescribed any drug with a specifi ed EOL care indication. The most common palliative EOL drugs were morphine (71.4% of patients), midazolam (55.0%), glycopyrronium (46.9%), and haloperidol (46.9%) (see Table I ). Palliative EOL drugs were prescribed to 74.2% of the study population, either alone (26.9%) or concomitantly with curative/preventive drugs (47.3%). Curative/preventive drugs were prescribed to 72.5% of patients (alone 25.2%). Some 95.7% of palliative EOL drugs were prescribed as needed. Patients had standing prescriptions of median (25th -75th percentile) three (zero -eight) palliative EOL drugs and three (zero -four) curative/preventive drugs on the date of death. There was a median period of two (zero -seven) days from prescription to death for palliative EOL drugs.
Having prescriptions of palliative EOL drugs at death was associated with length of stay Ͼ 16 months (AOR 2.10, 95% CI 1.13 -3.95), cancer (2.12, 1.19 -3.76), age (1.03, 1.005 -1.05), and being at NH B (3.53, 1.99 -6.25) or NH C (4.20, 2.36 -7.48) ( Table IV) . Figure 1 shows that the proportion of patients for whom at least one palliative EOL drug was initiated, or at least one curative/preventive drug was discontinued, increased in the last week before death and peaked on the day of death. 
Discussion
Our study shows that palliative EOL drugs were commonly prescribed for NH patients during the last days of life. NH, a diagnosis of cancer, and long stay were associated with palliative EOL drug therapy. Most initiations of palliative EOL drugs, and most withdrawals of curative/preventive drug therapy, occurred on the day of death.
Strengths and weaknesses
The study population comprised patients from all types of wards, and although the diagnostic data are not validated this broad diversity is expected to refl ect NH populations in general.
With the exception of short-term care patients from NH A, all patients admitted and deceased in three NHs during the fi ve-year study period were included, limiting selection bias. Only three institutions participated in the study, limiting statistical power and to some extent generalizability.
A complete set of medication data for all patients was collected. The electronic patient record did not include information on whether prescribed medication was actually taken, leading to possible overestimation of drug use. Prescribed medication, on the other hand, may refl ect the doctor ' s treatment decisions more appropriately than given medication. This point is particularly important for palliative drugs, which comprised almost exclusively as-needed drug prescriptions. Use of indication text secured a comprehensive defi nition of palliative EOL drugs, while inclusion of specifi cally recommended palliative EOL drugs ensured that these prescriptions were not missed regardless of missing EOL key words in the indication text. Restricting the latter to injectables, we excluded prescriptions less specifi c to the dying patient, such as opioid tablets, oral suspensions, and patches. Injectable antipsychotics and benzodiazepines may on occasion be used to treat neuropsychiatric symptoms in dementia. A median of two days from prescription to death makes it less likely, though, that these prescriptions were issued for their non-palliative indications. Although anticholinergics have other indications, in injectable form, glycopyrronium and scopolamine are seldom used for nonpalliative purposes in NHs.
Comparison with other studies
There are few other studies reporting on drug therapy at the EOL in the general NH population, and with considerably smaller sample sizes. Decreased overall treatment intensity has been found in patients perceived as dying, across NH, hospital, and general practice settings in the Netherlands [13] . Patients with dementia dying in American NHs were prescribed unchanged total numbers of drugs, palliative medications replacing other medications [9] .
Our study adds to previous knowledge showing that NH patients with the longest duration of stay, or a diagnosis of cancer, were more likely to receive palliative EOL drugs on the day of death than those without these characteristics. More than 80% of longterm care patients have dementia [14] , interfering with the communication of suffering, analgesia, and EOL care [15 -17] . Accurate survival prediction for patients with advanced dementia is diffi cult, and may hinder palliative care [18] . Longer NH stays may nevertheless allow time for advance care planning and staff familiarity with the patient, thus facilitating palliation, and perhaps explaining the association found with the longest stays. Patients with cancer often have expected deaths with a typically rapid functional decline, and are at the centre of palliative guidelines [7, 19] . Palliative drug therapy for this group was therefore expected. A diagnosis of dementia, heart failure, chronic pulmonary disease, infection, or hip fracture was not associated with initiation of palliative drugs. This may indicate death coming unexpectedly. For respiratory distress in chronic pulmonary disease there may also be a reservation among physicians to prescribe morphine and benzodiazepines, as they inhibit respiration.
An evidence base for EOL care in non-malignant conditions, which are prevalent in the general NH population, is scarce [20] . We found a high treatment rate with palliative drugs (73.9% overall, 71.9% for morphine), in line with 77% of NH patients with advanced dementia in the Netherlands receiving opioids. Despite extensive prescribing, the Dutch study found that symptoms of pain, shortness of breath, and agitation were prevalent, suggesting that a prescribed drug is no guarantee of satisfactory symptom control [21] . For this, factors such as close symptom assessment as well as appropriate drug dosage and administration are required.
Palliative drug therapy increased and curative/ preventive drug treatment decreased in the last week of life, most changes taking place on the day of death. A recent study in long-term care facilities in Canada found that care only changed substantially to palliative in nature during the last hours or days of life, calling for earlier awareness of impending death [22] . Initiation of palliative drugs is not to be expected for all dying patients, nor does it depend only on staff competence. Less palliative drug therapy could also come from less need for it, by having a shorter terminal phase, or less burdensome symptoms. Little is known about the identifi cation and duration of the dying phase in NH patients and for how many it lasts long enough to allow for pharmacological response. Distinct death trajectories have been described for patients with different diseases [23] , and timing of palliative care for patients with non-malignant diagnoses has been shown to be particularly challenging [24] . Yet, relatively accurate prediction of survival for these patients in NHs has been shown to be feasible, though only in the last seven days of life [25] .
NH A had a lower proportion of patients prescribed palliative medications at death. Differences Figure 1 . Proportion of patients (%) for whom at least one palliative EOL drug was initiated, or at least one curative/preventive drug was discontinued during the last 14 days of life.
in prescribing culture between doctors may be one explanation. For the present study we did not collect this variable.
Meaning of the study
Palliative drug prescriptions and drug therapy changes are common for NH patients on the last day of life. Extensive curative/preventive drug therapy and comprehensive changes in drug treatment on the day of death may both point to the known prognostication diffi culties in the multimorbidity characterizing NH populations. Improvements of EOL care in NHs must address prognostication and an early response to palliative needs.
